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Intraocular pressure (IOP) is an important risk factor for the development and 
progression of glaucoma. In recent years, The Ocular Hypertension Treatment Trial 
has demonstrated that IOP reduction can prevent the development of glaucoma among 
individuals with ocular hypertension and can reduce the risk of glaucoma progression 
among subjects with both normal and elevated IOP. The impact of both short-term 
and long-term IOP variability on progression risk has also been explored, with many 
(but not all) studies finding a positive relationship between greater IOP variability and 
higher rates of glaucomatous progression or development. 
Treatment of glaucoma aims on the reduction of intraocular pressure (IOP).
 
While 
several laser and surgical therapies are available, topical medication continues to be a 
commonly utilized initial treatment option. Due to their once daily dosing, excellent 
efficacy, and favourable side effect profile, the prostaglandin analogues are frequently 
chosen as the first line medication for the reduction of IOP in most forms of glaucoma 
and ocular hypertension.
 
It is believed that prostaglandin analogues lower IOP 
primarily by increasing aqueous outflow through the uveoscleral pathway.
 
Based on 
more recent evidence, these medications may also augment the traditional outflow 
pathway through the trabecular meshwork and Schlemm's canal. There are currently 
several molecules within the prostaglandin analogue class that are commercially 






Travoprost ophthalmic solution 0.004% is a prostaglandin analog available 
throughout the global marketplace and indicated for IOP reduction in subjects with 
open-angle glaucoma or ocular hypertension. Travoprost ophthalmic solution has 
been formulated with a variety of preservatives. 
 
Mechanism of action 
Travoprost, like the other prostaglandin analogues latanoprost and bimatoprost, is a 
synthetic analogue of prostaglandin F2α. Prostaglandins are a family of molecules 
found ubiquitously throughout most tissues and organs. They are synthesized 
enzymatically from fatty acids, and all contain 20 carbon atoms, including 5 in a ring 
formation. Their functions are diverse, and include roles in muscle constriction, 
inflammation, and platelet aggregation. These various functions are mediated by 
binding of specific prostaglandins to one or more of numerous prostaglandin 
receptors. The prostaglandin receptors are transmembrane, G-protein-coupled 
receptors. 
The travoprost molecule is an ester pro-drug that is hydrolyzed by corneal esterases 
into its active free-acid form. The IOP-lowering efficacy of all three prostaglandin 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 12:28:28 EET - 137.108.70.7
 4 
analogues is dependent upon interaction with the prostaglandin FP receptor, as 
evidenced by the lack of IOP reduction seen with these drugs in eyes of FP receptor-
deficient mice. Once hydrolyzed in the eye, travoprost acid then binds to 
prostaglandin FP receptors in both the ciliary muscle and the trabecular meshwork. In 
cultured cells from both ciliary muscle and trabecular meshwork in human, rat, and 
mouse models, travoprost acid exhibits higher binding affinity and higher potency at 
the FP receptor, and also demonstrates higher selectivity for the FP receptor than for 
other prostaglandin receptors, than either latanoprost or bimatoprost FP-receptor 
binding by prostaglandin F2α and its analogues results in numerous physiologic 
responses within ciliary muscle cells. These include phosphoinositide turnover, 
intracellular Ca
2+
 mobilization, and mitogen-activated protein (MAP) kinase 
activation. In addition, FP receptor activation indirectly stimulates formation of 
cAMP via activation of the coupled G-protein by stimulating the synthesis of PGE2. 
This in turn leads to increased cellular levels of c-Fos and c-Jun within the nuclei of 
ciliary smooth muscle cells. These two proteins can heterodimerize, forming a 
complex that binds to the promoter regions of some genes, thus promoting their 
transcription. The results of these FP receptor-mediated intracellular signals include 
increased production of several matrix metalloproteinases (MMPs), specifically 
MMP-1, -2, -3 and -9, in cultured human ciliary smooth muscle cells. MMPs are a 
family of enzymes that are capable of degrading all extracellular matrix components, 
including collagen. In monkey eyes, topical exposure to prostaglandin F2α reduces 
collagen types I, II, and IV within the ciliary muscle. Remodeling of the extracellular 
matrix of the ciliary body is hypothesized to lower IOP by creating or increasing 
spaces between the ciliary muscle fiber bundles, thus increasing outflow through the 
uveoscleral pathway. 
 
Travoprost and preservatives 
 
Travoprost (Travatan, Alcon, Fort Worth, TX) was first approved by the Food and 
Drug Administration (FDA) in 2001. The multi-dose bottle for travoprost available in 
the United States was originally preserved with the detergent preservative 
benzalkonium chloride (BAK). This formulation has been previously shown to 
significantly lower IOP during both the diurnal and nocturnal periods in patients with 
open angle glaucoma and ocular hypertension. A report by Sit et al has demonstrated 
a durable IOP lowering response of travoprost with BAK for 41 to 63 hours after last 
dose.
 
Despite its efficacy and widespread use in ophthalmic medications, chronic use 
of BAK can have several negative effects on ocular tissues in specific patient 
populations.
 
Prolonged BAK exposure in cell culture models results in arrest of cell 
growth, apoptosis, and even necrosis at very high doses. These detrimental effects are 
implicated in ocular surface disease that is frequently present in patients taking 
multiple BAK-preserved medications. In 2006, BAK was removed from travoprost 
and replaced with a novel ionic-buffered preservative system called sofZia (Travatan 
Z, Alcon). After application on the ocular surface, sofZia components break up into 
innate ingredients with the theoretical benefit of decreased hyperemia and improved 
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1.3. Rationale for the study    
 
 
The decision to select medical therapy options relies primarily on the efficacy of the 
available medications in various therapeutic trials. Sadly, most published studies only 
evaluate the short-term, daytime efficacy of medical therapy. Travoprost is 
increasingly becoming a popular first-line monotherapy option for POAG patients as 
there is cumulative evidence suggesting good quality of short term 24-hour IOP 
control with low fluctuation, especially with evening administration. As POAG is a 
24-hour, lifelong disease, an ideal antiglaucoma medication should be successful in 
reducing IOP during day and night. Importantly, 24-hour studies have confirmed that 
24-hour IOP monitoring can significantly modify individualized glaucoma care in 
many glaucoma patients. This study will examine whether the IOP-reduction of 






2. TRIAL OBJECTIVES  
 
 
The primary objective is to evaluate the IOP-lowering efficacy of travoprost with 
sofZia used as a first-line therapy during a 12-weeks follow-up period 
 
Secondary objectives: 
-evaluation of subjective symptoms (ie, burning, foreign-body sensation, itching, and 
stinging) 
-evaluation of objective clinical signs such as conjunctival hyperemia, iris color 
darkening and eyelash darkening, thickening and lengthening, localized pigmentation 






3. STUDY DESIGN 
 
This is an observational, prospective study for Travoprost with sofZia in patients with 
open-angle glaucoma or ocular hypertension. A total of 165 newly diagnosed patients 
with open-angle glaucoma or elevated intraocular pressure will be enrolled and will 
be followed up for 12 weeks after starting them on travoprost 0.004% BAK-free once 
daily. The initiation of this treatment modality will be based on the decision of the 
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4.1. Inclusion criteria 
 
This study will enrol newly diagnosed, previously untreated POAG patients who 
exhibit characteristic glaucomatous disc damage and visual field loss. Subjects must 
meet all of the following inclusion criteria to be eligible for enrolment into the study: 
 
-age above 45 years 
 
-no previous ocular surgery other than uncomplicated phacoemulsification cataract     
surgery performed at least 6 months before entering the study 
 
-open-angle by gonioscopy (grades III and IV according to the Shaffer classification) 
 
-untreated IOP between 21 and 35 mm Hg at 10:00 AM±1 hour verified by 2 separate 
measurements (enrollment IOP) 
 
-signed informed consent 
 
 
4.2. Exclusion criteria 
 
Subjects presenting with any of the following exclusion criteria will not be included 
in the study: 
 
-any type of glaucoma other than POAG 
 
-corneal or other anatomic conditions making applanation tonometry unreliable 
 
-central corneal thickness <=500 µm or >=600 µm 
 
-signs or history of macular edema, herpetic, or other ocular inflammatory disease 
 
- history of allergy or adverse event related to the study medication 
 
-history or suspicion of poor adherence to medical therapy 
 
-best-corrected visual acuity <0.4 (Snellen) 
 
-cup-to-disc ratio >0.7 
 
-mean deviation (MD) worse than -15 dB in Humphrey 24-2 SITA standard perimetry 
(Humphrey Visual Field Analyzer; Carl Zeiss Meditec Inc., Dublin, CA) 
 
-the possibility of significant visual deterioration and optic nerve damage due to 
participation to the study according to the principal investigator’s judgment. 
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- patients who are pregnant or who can become pregnant during the study  
 
-patients with IOP higher than 30 mmHg at baseline visit or those who had undergone 
glaucoma filtrating surgeries  
  
Patients will be also excluded if they are unable to understand the study procedures, 





5. STUDY PROCEDURES 
 
During an initial eligibility visit, all qualified patients will undergo a detailed 
ophthalmic examination and their ocular and systemic clinical data will be recorded. 
Study participants will be admitted at the Ophthalmologic Department of the 
University General Hospital of Thessaloniki, AHEPA for an untreated 24-hour IOP 
evaluation (baseline visit) with Goldmann tonometry. The IOP will be recorded at 
10:00 AM, 2:00 PM, 6:00 PM, 10:00 PM, 2:00 AM, 6:00 AM, and 10:00 AM (±1 h). 
The day before the 24-hour IOP assessment, a reliable 24-2 SITA standard visual field 
test will be performed (Humphrey Visual Field Analyzer; Carl Zeiss Meditec Inc.). 
Subsequently all study patients will be assigned to topical therapy with travoprost 
0.004% eye-drops with sofZia (Travatan Z, Alcon Laboratories Inc.) administered 
once in the evening (8:00 PM) in both eyes in accordance with current clinical 
practice. To ensure that the target IOP will be reached, according to the principal 
investigator’s judgment, a safety visit will be performed approximately 4 weeks after 
treatment initiation. The predetermined range of target IOP reduction selected in this 
study with travoprost monotherapy will range between 20% and 30%. After this visit, 
all patients will be scheduled for a visit at  12 weeks after the baseline visit at 16:00 
AM±1 hour. This schedule of follow-up will be maintained for the whole duration of 
the trial. A comprehensive clinical examination will be performed at each visit 
recording the possible subjective symptoms and ojective clinical signs. Enrolled 
patients will continue on travoprost monotherapy as long as their target IOP will be 
successfully maintained. Calibrated Goldmann tonometers will be used throughout the 




5.1. Assessment  of study endpoints 
 
Intraocular pressure reduction 
 





Subjective symptoms will be evaluated using a four-point scale ranging from “no 
symptoms,” “mild symptoms,” “moderate symptoms” to “severe symptoms.”  
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Iris color darkening and eyelash darkening, thickening and lengthening 
 
Investigators will take photographs of the anterior surface of the eyes (including iris, 
conjuctiva and eyelashes) at baseline and follow-up visits, allowing objective 
assessments of the recorded changes of iris colour darkening, eyelash darkening, 
thickening and lengthening since baseline. 
 
The baseline colour of the iris will be assessed by an ophthalmologist and is classified 
into one of the five groups: homogeneously brown, blue brown, gray brown, green 
brown and yellow brown. 
 
Possible degrees of iris colour darkening at follow-up visits will be assessed by the 
ophthalmologist. The change will be classified into one of six categories: 
 
 Decrease- a reduction or lightening of pigmentation 
 No change- no visible change in pigmentation recorded 
 Slight- a slight but clearly visible increase in pigmentation 
 Moderate- the increase in pigmentation is more than slight but not striking 
 Marked- a strong increase in pigmentation 
 Not evaluable 
 
Possible degrees of eyelash darkening/thickening at follow-up visits will be classified 
by the ophthalmologist into one of six categories as described above (i.e. decrease, no 
change, slight increase, moderate increase, marked increase and not evaluable) 
 
The longest eyelash (mm) measured by calliper or ruler will be recorded at baseline 




Localized pigmentation of conjuctiva, iris and choroid 
 
The anterior surface photographs can be used to assess pigmentation of conjuctiva and 
iris.  Investigators will also take retinal fundus photographs at baseline and follow-up 
visits, allowing objective assessment of the recorded changes in choroid pigmentation. 
The previous existence of nevi or freckles of conjuctiva, iris and choroid will be 
recorded at baseline (yes/no). Possible degrees of change at follow-up visits will be 
recorded by the ophthalmologist and will be classified into one of six categories: 
 
 Increased number  
 Increased size (height, length and width) 
 Changing colour (darkening or lightening) 
 Changing uniformity of the colour (increase or decrease) 
 Increased irregularity of the border/decreased sharpness of the border 
 No change 
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Conjuctival hyperemia will ne assessed and graded by ophthalmologist at baseline 
and follow-up visits as follows: 
 
0 = None           Normal: few vessels of palpebral or bulbar conjuctiva easily observed 
 
1 = Mild            Reddening of the palpebral or bulbar conjuctiva 
 
2 = Moderate     Bright reddening of the palpebral or bulbar conjuctiva 
 




5.2. Subject withdrawal 
 
Subjects or legally accepted representatives may withdraw from the study at any time 
at their own request, or they may be withdrawn at any time at the discretion of the 
ophthalmologist or sponsor for safety, behavioral, or administrative reasons. In any 
circumstance, every effort should be made to document subjecyt outcome, if possible. 
The ophthalmologist should inquire about the reason for withdrawal and follow-up 
with the subject regarding any unresolved adverse events. 
 
If the subject withdraws from the study, and also withdraws consent for disclosure of 
future information, no further evaluations should be performed, and no additional data 
should be collected. The sponsor may retain and continue to use any data collected 







6. STATISTICAL CONSIDERATIONS 
 
The primary endpoint of the study is the  mean IOP reduction achieved after 12 weeks 
of treatment with Travoprost with sofZia monotherapy. For this reason mean IOP at 
baseline will be estimated as well as mean IOP at endpoint i.e. 12 weeks. Both eyes 
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6.1. Sample size determination 
 
In order to estimate the appropriate sample size needed, t-test dependent sample will 
be used. As proposed by Harvey B Dubiner and Robert Noecker in Clin.Opthalmol. 
2012; 6: 525–531 mean IOP reduction by 12th week was estimated to be -7.6 mmHg 
(-7.6 +/- 3.3) 
 
Using G Power 3.0.10. and given that a=0.05 and power (1-β)= 0.8 we have the 
following output parameters: 
 
Noncertrality parameter δ= -2.8 
 




Total sample size= 150 
 
Taking into consideration that an expected dropout we have to increase this number 




6.2. Statistical Analysis 
 
 
The  target of the present study will be to estimate the mean IOP reduction achieved 
by the 12
th
 week in patients treated with travoprost monotherapy. For this reason, 
mean IOP at baseline and mean IOP at endpoint (12
th
 week- primary outcome) at 
16:00 AM will be calculated and then compared with each other using t-test 
dependent samples and 95% Confidence Interval.  
 
In addition demographic characteristics will be described as age, sex, ethnicity, co-
existent diseases (hypertension, diabetes mellitus). 
 
As for the secondary outcomes, mean IOP at 4-week visit will be estimated and 
compared to mean IOP at baseline using t-test dependent samples. Furthermore, 
statistics will present the occurrence of subjective symptoms and objective clinical 
signs, as ocular hyperemia, iris colour darkening and eyelash darkening, thickening 
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7. ADVERSE EVENT REPORTING 
 
 
7.1. Adverse events 
 
All observed or volunteered adverse events regardless of suspected causal relationship 
to travoprost will be recorded. 
 
For all adverse events, the ophthalmologist must pursue and obtain information 
adequate both to determine the outcome of the adverse event and to assess whether it 
meets the criteria for classification as a serious adverse event. For all the adverse 
events sufficient information should be obtained by the ophthalmologist to determine 
the causality of the adverse event. The ophthalmologist is required to assess causality. 
For adverse events with a causal relationship to travoprost, follow-up by the 
ophthalmologist is required until the event or its sequelae resolve or stabilize at a level 
acceptable to the ophthalmologist. 
 
 
7.2. Reporting period 
 
For serious adverse events, the reporting period begins from the time that the subject 
provides informed consent, which is obtained prior to the subject’s participation in the 
study, through the entire study period or 28 calendar days after the last administration 
of travoprost within the observational period, whichever is latest. 
 
 
7.3. Definition of an Adverse Event 
 
 
An adverse event is any untoward medical occurrence in a clinical investigation 
subject administered a product or medical device: the event needs not necessarily 
have a causal relationship with the treatment or usage. Adverse events may include: 
 
 Abnormal test findings 
 Clinically significant symptoms and signs 
 Changes in physical examination findings 
 Hypersensitivity 
 Progression/worsening of underlying disease 
 
Additionally, they may include signs or symptoms resulting from: 
 
 Drug overdose 
 Drug abuse 
 Drug misuse 
 Drug interactions 
 Drug dependency 
 Exposure during pregnancy 
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8.1. Executive Committee  
The EC consists of members of the academic leadership of the study and 1 member 
from the sponsoring company. The EC will ultimately be responsible for the conduct 
of the study including addressing any Data Monitoring Committee recommendations 
and overseeing publication of the results.  
 
8.2. Steering Committee  
A Steering Committee will be formed consisting of members who are lead 
investigators from each country/region. The Steering Committee will advise and assist 
the EC with regard to the scientific and operational aspects of the study.  
 
8.3. Independent Data Monitoring Committee  
This study will be conducted under the auspices of an independent Data Monitoring 
Committee (DMC), which will monitor the progress of the study and ensure that the 
safety of subjects enrolled in the study is not compromised. The DMC will have a 
chairperson and include at least 2 cardiologists, a neurologist, as well as a statistician. 
This committee will review accumulating data on a regular basis, and may request to 
review partially unblinded or unblinded accumulating data. The DMC will make 
recommendations to the Executive Committee and Sponsor regarding the continuing 
safety of subjects currently enrolled and yet to be enrolled in the trial. At all times 
during the course of the study, the DMC may request access to unblinded data if 
needed.  
 
8.4 Clinical Endpoint Committee  
The Clinical Endpoint Committee (CEC), composed of experts in the relevant fields, 
will review, in a blinded manner, all reported study outcomes to provide consistency 
and validity in the assessment of outcomes. Their decisions will be based on blind 







9. ETHICAL CONSIDERATIONS  
 
This study will be conducted in compliance with the protocol, the ethical principles 
set forth in the Declaration of Helsinki, the ICH Guideline E6 for GCP and applicable 
regulatory requirement(s). Good clinical practice (GCP) is an international ethical and 
scientific quality standard for designing, conducting, recording, and reporting research 
studies that involve the participation of human subjects. Compliance with this 
standard provides public assurance that the rights, safety, and well-being of study 
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subjects are protected, consistent with the principles that have their origin in the 




9.1. Institutional Review Board/Independent Ethics Committee  
 
The protocol and any amendments, the Investigator’s Brochure, the subject informed 
consent and any information on compensation for study-related injuries or payment to 
subjects, will receive IRB/IEC approval prior to initiation of the study. During the 
study the investigator will send to the IRB any reports of adverse events that are 
serious, unlisted, and associated with the investigational drug and any new 
information that may adversely affect the safety of the subjects or the conduct of the 
study.  
Study personnel involved in conducting this study will be qualified by education, 
training, and experience to perform their respective task.  
 
 
9.2. Informed Consent  
 
Before a subject’s participation in the study, it is the Investigator’s responsibility to 
obtain freely given consent, in writing, from the subject or a legally acceptable 
representative after adequate explanation of the aims, methods, anticipated benefits, 
and potential hazards of the study and before any protocol-specific procedures or any 
study drugs are administered.  
The written ICF should be prepared in the local language(s) of the potential subject 
population. The informed consent should be approved by the IRB prior to being 
provided to potential subjects.  
The written informed consent form and any other written information to be provided 
to subjects should be revised whenever new information becomes available that may 
be relevant to the subject’s consent. Any revisions to the written informed consent 
form and/or to other written information provided to the subject should be approved 
by the responsible IRB in advance of use.  
Subjects unable to give their written consent (e.g., stroke subjects, or subjects with 
severe dementia) may only be enrolled in the study with the consent of a legally 
acceptable representative. The subject must also be informed about the nature of the 
study to the extent compatible with the subject’s understanding.  
If a subject or a subject’s legally acceptable representative is unable to read, an 
impartial witness should be present during the entire informed consent discussion.  
Subjects may withdraw consent from participation in the study at any time. In the 
event a subject withdraws consent to receive study drug, the site may (with the 
subject’s agreement) continue to contact the subject, general practitioner, and any 








Institutional Repository - Library & Information Centre - University of Thessaly




9.3. Subject Confidentiality  
 
The Investigators and the Sponsor will preserve the confidentiality of all subjects 
taking part in the study, in accordance with GCP and local regulations.  
The Investigator must ensure that the subject’s anonymity is maintained. On the 
eCRFs or other documents submitted to the Sponsor or the CRO, subjects should be 
identified by a unique subject identifier as designated by the Sponsor. Sponsor 
personnel whose responsibilities require access to personal data should agree to keep 
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